A phase I, open-label, single-dose, randomized, cross-over study to evaluate BLZ945 granule for suspension in healthy participants: relative bioavailability in comparison to BLZ945 capsule and food effect - CBLZ945C12102

Start Date30 Oct 2023

Sponsor / Collaborator-

NCT04066244

/ TerminatedPhase 2

An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28

It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.

Start Date30 Dec 2019

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT02829723

/ TerminatedPhase 1/2

A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors

The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors.

Start Date21 Oct 2016

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

100 Clinical Results associated with Sotuletinib

100 Translational Medicine associated with Sotuletinib

100 Patents (Medical) associated with Sotuletinib

Literatures (Medical) associated with Sotuletinib

01 Aug 2025·BRAIN BEHAVIOR AND IMMUNITY

Microglia endotoxin tolerance is retained after enforced repopulation

Article

Author: Holtman, Inge R ; Eggen, Bart J L ; Medeiros-Furquim, Tiago ; Schilder, Edwin ; Miedema, Anneke ; Kooistra, Susanne M ; Brouwer, Nieske

Microglia are crucial for CNS homeostasis and are involved in a wide range of neurodegenerative and neuroinflammatory diseases. Systemic inflammation and infections can contribute to neurodegeneration later in life by affecting microglia. Like other innate immune cells, microglia can develop innate immune memory (IIM) in response to an inflammatory challenge, altering their response to subsequent stimuli. IIM can ameliorate or worsen CNS pathology, but it is unclear if IIM can be reversed to restore microglia functions. Here, we investigated whether microglia depletion-repopulation by inhibition of the colony-stimulating factor 1 receptor with BLZ945 reversed LPS-induced microglia endotoxin tolerance in mice. Repopulated microglia displayed a reduced expression of homeostatic genes and genes related to mitochondrial respiration and TCA cycle metabolism and an increased expression of immune effector and activation genes. Nonetheless, the blunted inflammatory gene response after LPS-preconditioning was retained after a depletion-repopulation cycle. Our study highlights the persistence of endotoxin tolerance in microglia after a depletion-repopulation cycle, which might impact the potential effectiveness of strategies targeted at microglia depletion for clinical applications.

01 Jul 2025·BIOMATERIALS

Injectable oxidized high-amylose starch hydrogel scaffold for macrophage-mediated glioblastoma therapy

Article

Author: Li, Qiaofeng ; Liu, Zhuang ; Yu, Zhengquan ; Chen, Gang ; Chao, Yu ; Wu, Yuzhe ; Ma, Cheng ; Wang, Jiahe

Glioblastoma, characterized by rapid proliferation and invasiveness, is largely resistant to current treatment modalities. A major obstacle is the blood-brain barrier (BBB), which restricts the delivery of therapeutic agents as well as the infiltration of effective immune cells into glioblastoma. In this study, we developed an injectable oxidized high-amylose starch hydrogel (OHASM) to serve as a biomaterial scaffold for the delivery of macrophages and macrophage-polarizing drugs, aiming to bypass the BBB and enhance glioblastoma treatment. The in vitro and in vivo experiments confirmed the efficacy of the hydrogel in loading and delivering macrophages and polarizing drugs against glioblastoma. Additionally, the hydrogel's interconnected porous structure was conducive to cellular growth and activity, and its slow release of therapeutics contributed to the extended survival of treated mice in a mouse GL261 glioblastoma tumor model. The immunological mechanisms underlying the therapeutic efficacy were further elucidated, revealing the potential of the hydrogel system to modulate macrophage polarization and induce apoptosis in tumor cells via the poly ADP-ribose polymerase (PARP) pathway. The study underscores the potential of the hydrogel-based macrophage delivery strategy as an effective and safe treatment for glioblastoma, offering a promising avenue for clinical management of this aggressive brain cancer.

01 Jun 2025·MOLECULAR PSYCHIATRY

Astrocytes release ATP/ADP and glutamate in flashes via vesicular exocytosis

Article

Author: Dai, Ruicheng ; Wu, Zhaofa ; Li, Heng ; Geng, Peiyao ; Luo, Minmin ; Zhao, Yuqing ; Weng, Danwei ; Wu, Wenting ; Li, Yulong ; Yu, Fengting ; Lin, Rui

Astrocytes regulate brain functions through gliotransmitters like ATP/ADP and glutamate, but their release patterns and mechanisms remain controversial. Here, we visualized ATP/ADP and glutamate response following astrocyte activation and investigated their mechanisms in vivo. Employing cOpn5-mediated optogenetic stimulation, genetically encoded fluorescent sensors, and two-photon imaging, we observed ATP/ADP released as temporally prolonged and spatially extended flashes that later converted to adenosine. This release occurs via Ca²⁺ and VNUT-dependent vesicular exocytosis. Additionally, astrocytes also release glutamate in flashes through TeNT-sensitive exocytosis, independent of ATP/ADP release. ATP/ADP released by astrocytes triggers further ATP/ADP release from microglia through P2Y12- and VNUT-dependent mechanisms. VNUT in astrocytes and microglia also contributes to ATP/ADP release under LPS-induced brain inflammation. These findings establish Ca²⁺-dependent vesicular exocytosis as a key mode of action, reveal intricate astrocyte-microglia interactions, and suggest a role for gliotransmission in brain inflammation. Furthermore, the methodologies may provide valuable tools for deciphering glial physiology and pathophysiology.

News (Medical) associated with Sotuletinib

09 Mar 2023

·www.prnewswire.com

Despite Market Access Hurdles and Limited Familiarity Hampering Initial Uptake, Neurologists Project Robust Future Use of Relyvrio for the Treatment of ALS, According to Spherix Global Insights

Recent research suggests Relyvrio will benefit from the limited number of therapies approved to slow decline in ALS EXTON, Pa., March 9, 2023 /PRNewswire/ -- With the FDA approval of Amylyx's Relyvrio (AMX0035; sodium phenylbutyrate and taurursodiol) for amyotrophic lateral sclerosis (ALS) in September 2022, patients gained access to only the third novel molecule approved for this rare, neurodegenerative disease. Mitsubishi Tanabe's edaravone formulations (IV Radicava and oral Radicava ORS) and different riluzole formulations (generics, ITF Pharma's thickened oral suspension Tiglutik, and Mitsubishi Tanabe's oral film Exservan) are the only other approved disease-modifying therapies approved for ALS. At this early stage of launch, the majority of neurologists/neuromuscular specialists (n=68) surveyed in February 2023 reported actively discussing Relyvrio with their ALS patients, typically at their next scheduled visit with relevant candidates. Respondents consider ALS patients with early-stage disease to be the most appropriate candidates for Relyvrio, suggesting that HCPs already perceive it as a first-line therapy. However, even with these generally positive opinions on Relyvrio, reimbursement hassles and out-of-pocket costs are currently key barriers to use. Specifically, data reveal that two in five ALS patients deemed clinically appropriate for Amylyx's brand are not able to receive it due to coverage or co-pay issues. As mentioned by one neurologist unaided when queried on the biggest disadvantage of Relyvrio, " Access is absolutely ridiculous. I spent so much of my time going back-and-forth and it takes forever to get the medication." Delays in access to medications are felt especially acutely in this market and are underscored as a particularly greater barrier given the often-rapid progression of the disease and need for fast treatment. With half of neurologists never having been visited by an Amylyx sales representative, lack of familiarity is also a primary obstacle to increased Relyvrio use. Notably, only a minority of respondents consider Amylyx to be executing well on Relyvrio's launch and few feel that the manufacturer has given them the necessary information to confidently initiate patients on the brand. When asked for advice to Amylyx on Relyvrio's launch, an interviewed respondent highlighted the need for additional outreach: " The biggest thing I would recommend to them is they are not doing as great of a job getting the word out. I don't know if it's because they're still hesitant and waiting for the rest of the data to come out." Despite these obstacles, the majority of neurologists anticipate initiating trial of Relyvrio in their ALS patients over the next six months, likely in combination with other therapies, such as riluzole, in order to provide maximum therapeutic benefit for patients. Even with the noted advance that Relyvrio brings to the market, neurologists are also keen to point out that there is still a large unmet need for new and advanced treatment options. Given the large pipeline of diverse emerging therapies in ALS, including Biogen's tofersen, Apellis Pharmaceuticals' pegcetacoplan, GSK/Alector's latozinemab (GSK4527223/AL-001), Novartis' BLZ945, Sanofi's SAR443820, Ionis Pharmaceuticals' ION363, and Cytokinetics' reldesemtiv, there is hope for new options to bring relief to this underserved patient population. Spherix will continue to track the launch performance of Relyvrio in the ALS market via the Launch Dynamix™: Relyvrio (Amylyx) in ALS report series and will begin tracking the launch of tofersen in ALS if approved on its April 25th, 2023 PDUFA date. About Launch Dynamix™ Launch Dynamix: Relyvrio (Amylyx) in ALS is an independent service providing quarterly deep dives into launch benchmarks, promotional activity, barriers to uptake, and patient types gravitating to the new brand. About Spherix Global Insights Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry. The company's unique service offerings are powered by deep therapeutic knowledge, the Spherix Network specialty physician panel, and commercially relevant analyses to enable strategic decision-making by our valued customers. A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology. To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter. Spherix Global Insights Contacts Emma McFadden, Senior Insights Director, Neurology [email protected] Scott Upham, Corporate Communications [email protected] NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement by any company, brand, or product aforementioned. SOURCE Spherix Global Insights

Drug Approval

21 Feb 2023

·www.prnewswire.com

Amyotrophic Lateral Sclerosis Pipeline Booms as 100+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

The prevalence of amyotrophic lateral sclerosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of amyotrophic lateral sclerosis and the growing research and development activities to develop novel therapies to treat amyotrophic lateral sclerosis to drive the market. The companies developing the potential therapies in the last stage of development include Biogen, AB Sciences, Helixmith, and several others. LAS VEGAS, Feb. 21, 2023 /PRNewswire/ -- DelveInsight's ' Amyotrophic Lateral Sclerosis Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline amyotrophic lateral sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the amyotrophic lateral sclerosis pipeline domain. Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report DelveInsight's amyotrophic lateral sclerosis pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for amyotrophic lateral sclerosis treatment. Key amyotrophic lateral sclerosis companies such as Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos, ZZ Biotech, LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others are evaluating new amyotrophic lateral sclerosis drugs to improve the treatment landscape. Promising amyotrophic lateral sclerosis pipeline therapies in various stages of development include BIIB067, FAB122, ABBV-CLS-7262, Trametinib, BIIB105, AstroRx, Dazucorilant, AP-101, RAPA-501, ION-363, Reldesemtiv, MN-166, RT001, Fasudil, SAR443820, PTC857, ANX005, DNL343, RNS60, BIIB100, CNMAu8, 18F-OP-801, Pegcetacoplan (APL-2), Cu(II)ATSM, KNS-760704, IFB-088, LAM-002A, CK 0803, 3K3A-APC, QRL-201, Dexpramipexole, AL001, PrimeC, BLZ945, AT-1501, and others. In February 2023, NeuroSense Therapeutics Ltd. and QuantalX Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device , announced a collaboration to improve early diagnosis and treatment of neurodegenerative diseases.In addition, the companies agreed that QuantalX's Delphi-MD would be used for early diagnosis and ongoing monitoring of trial participants in NeuroSense's planned future pivotal Phase III efficacy trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS), pending the successful conclusion of its ALS Phase IIb trial. In February 2023, Amylyx Pharmaceuticals, Inc. announced the completion of enrollment in PHOENIX, a global, 48-week, randomized, placebo-controlled Phase III clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) in people living with amyotrophic lateral sclerosis (ALS). Amylyx anticipates topline results in 2024. The study enrolled 664 participants living with ALS. In February 2023, UMass Chan Medical School signed a three-year sponsored research agreement with NeuShen Therapeutics Inc. to investigate a gene therapy treatment for amyotrophic lateral sclerosis, a rare neurological disease. Based in Shanghai and Boston, NeuShen is focused on developing innovative treatments for central nervous system disorders using adeno-associated virus-based gene therapy and small molecule delivery. In January 2023, Inflamed Pharma, part of the incubator and accelerator company Xlife Sciences, partnered with researchers at the University Medical Center Gottingen in Germany to develop its investigational therapy ProcCluster for the treatment of amyotrophic lateral sclerosis (ALS).The collaboration, led by Jan C. Koch, MD, a principal investigator at the university's Department of Neurology, will be focused particularly on investigating ProcCluster in cellular models of ALS. In January 2023, Amylyx Pharmaceuticals and Neopharm signed a license and distribution agreement to commercialize AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) to treat amyotrophic lateral sclerosis (ALS).Neopharm will commercialize the oral, fixed-dose medication in Israel, West Bank, Gaza, and the Palestinian Authority, subject to regulatory review and clearance.According to the agreement, Amylyx will grant exclusive rights to Neopharm for commercializing the therapy in the covered territory. In January 2023, uniQure N.V. and Apic Bio announced that they have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a rare, genetic form of ALS. Under the agreement, uniQure acquires global rights for the development and commercialization of APB-102, adding to its pipeline of gene therapies to treat neurological disorders. Request a sample and discover the recent advances in amyotrophic lateral sclerosis drug treatment @ Amyotrophic Lateral Sclerosis Pipeline Report The amyotrophic lateral sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage amyotrophic lateral sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the amyotrophic lateral sclerosis clinical trial landscape. Amyotrophic Lateral Sclerosis Overview Amyotrophic Lateral Sclerosis (ALS) is a rare neurological disease that affects the nerve cells (neurons) that control voluntary muscle movement (those muscles we choose to move). Voluntary muscles are responsible for movements such as chewing, walking, and talking. The disease is progressive, which means that the symptoms worsen over time. There is currently no cure for ALS and no effective treatment to slow or reverse the disease's progression. Muscle weakness or stiffness are common early ALS symptoms. Individuals gradually lose strength and the ability to speak, eat, move, and even breathe as all voluntary muscles are affected. Most people with ALS die from respiratory failure, usually within 3 to 5 years of the onset of symptoms. However, approximately 10% of people with ALS live for ten years or more. There is no single test that can definitively diagnose ALS. A detailed history of the symptoms observed by a physician during physical examination, as well as a review of the individual's full medical history and a series of tests to rule out other diseases, are used to make the ALS diagnosis. Find out more about drugs for amyotrophic lateral sclerosis @ New Amyotrophic Lateral Sclerosis Drugs A snapshot of the Amyotrophic Lateral Sclerosis Pipeline Drugs mentioned in the report: Learn more about the emerging amyotrophic lateral sclerosis pipeline therapies @ Amyotrophic Lateral Sclerosis Clinical Trials Amyotrophic Lateral Sclerosis Therapeutics Assessment The amyotrophic lateral sclerosis pipeline report proffers an integral view of amyotrophic lateral sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Amyotrophic Lateral Sclerosis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: RNA interference, Superoxide dismutase 1 expression inhibitors, Angiogenesis inhibitors, Colony stimulating factor inhibitors, Coronavirus-3C-like-proteinase inhibitors, Endopeptidase Clp inhibitors, Focal adhesion protein-tyrosine kinase inhibitors, Lyn protein-tyrosine kinase inhibitors, Macrophage colony-stimulating factor receptor modulators, Mast cell inhibitors, Platelet-derived growth factor receptor antagonists, Protein tyrosine kinase inhibitors, Proto oncogene protein c-kit inhibitors, Proto-oncogene protein c-fyn modulators, Type 3 fibroblast growth factor receptor antagonists, Angiogenesis inducing agents, Gene transference, Hepatocyte growth factor expression stimulants, G protein-coupled receptor modulators, HSP90 heat-shock protein modulators, Ion channel modulators, Antioxidants, NAD(P)H dehydrogenase (quinone) modulators, CD40 ligand inhibitors, Complement C1 inhibitors, Cyclo-oxygenase 2 inhibitors, DNA gyrase inhibitors Key Amyotrophic Lateral Sclerosis Companies: Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos, ZZ Biotech, LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others. Key Amyotrophic Lateral Sclerosis Pipeline Therapies: BIIB067, FAB122, ABBV-CLS-7262, Trametinib, BIIB105, AstroRx, Dazucorilant, AP-101, RAPA-501, ION-363, Reldesemtiv, MN-166, RT001, Fasudil, SAR443820, PTC857, ANX005, DNL343, RNS60, BIIB100, CNMAu8, 18F-OP-801, Pegcetacoplan (APL-2), Cu(II)ATSM, KNS-760704, IFB-088, LAM-002A, CK 0803, 3K3A-APC, QRL-201, Dexpramipexole, AL001, PrimeC, BLZ945, AT-1501, and others. Dive deep into rich insights for new drugs for amyotrophic lateral sclerosis treatment; visit @ Amyotrophic Lateral Sclerosis Medications Table of Contents For further information on the amyotrophic lateral sclerosis pipeline therapeutics, reach out @ Amyotrophic Lateral Sclerosis Drug Treatment Related Reports Amyotrophic Lateral Sclerosis Epidemiology Amyotrophic Lateral Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted amyotrophic lateral sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Amyotrophic Lateral Sclerosis Market Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key amyotrophic lateral sclerosis companies including Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, among others. Duchenne Muscular Dystrophy Market Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Duchenne muscular dystrophy companies including Edgewise Therapeutics, Pfizer, Daiichi Sankyo, among others. Nonsense Mutation Duchenne Muscular Dystrophy Pipeline Nonsense Mutation Duchenne Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonsense mutation Duchenne muscular dystrophy companies, including Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, among others. Becker Muscular Dystrophy Pipeline Becker Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key becker muscular dystrophy companies, including Epirium Bio, Ultragenyx, Strykagen, among others. Facioscapulohumeral Muscular Dystrophy PIpeline Facioscapulohumeral Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key facioscapulohumeral muscular dystrophy companies, including miRecule, Arrowhead Pharmaceuticals, Fulcrum Therapeutics, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Phase 3License out/inPhase 2

16 Jun 2021

·www.globenewswire.com

Amyotrophic Lateral Sclerosis Pipeline: Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight

Los Angeles, June 15, 2021 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Pipeline: Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight The pipeline of Amyotrophic Lateral Sclerosis is very vast and in the coming years, it is expected that the market will grow with the approval of late-stage products in the pipeline. DelveInsight’s ‘Amyotrophic Lateral Sclerosis (ALS) Pipeline Insights’ report offers exhaustive coverage of the emerging therapies and landscape in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. Some of the key highlights from the Amyotrophic Lateral Sclerosis Pipeline report: Request for Sample to know more about the therapies that are set to add maximum revenue @ Amyotrophic Lateral Sclerosis Emerging Therapies and Forecast The Amyotrophic Lateral Sclerosis Pipeline reports lay down a complete picture of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space and growth prospects across the Amyotrophic Lateral Sclerosis domain. Amyotrophic Lateral Sclerosis: Overview Amyotrophic Lateral Sclerosis is one of the groups of disorders known as motor neuron diseases, characterized by the progressive degeneration of nerve cells (motor neurons) in the brain and spinal cord eventually leading to their death. The condition hampers the communication between the nervous system and voluntary muscles of the body thus, affecting both the upper and lower motor neurons. For more information on emerging drugs, visit ALS Pipeline Analysis Amyotrophic Lateral Sclerosis Pipeline Drugs Request for Sample to know more @ Amyotrophic Lateral Sclerosis Pipeline Analysis, Key Companies and Futuristic Trends ALS Therapeutics Assessment The Amyotrophic Lateral Sclerosis Pipeline report proffers detailed insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets Get in touch with our Business executive for Informative Business Decisions, Licensing Services and Consulting Solutions Scope of the ALS Pipeline Report Coverage: GlobalKey Players: Biogen, Annexon Biosciences, Amylyx Pharmaceuticals, MediciNova, Novartis, AL-S Pharma, Acurastem, Orphazyme, AZTherapies, ALS TDI, Everfront Biotech, Q Therapeutics, Biohaven Pharmaceuticals, Neuropore Therapies, Retrotope, Seelos Therapeutics, among others.Key Amyotrophic Lateral Sclerosis Pipeline Therapies: BIIB067, ANX005, AMX0035, MN-166, BLZ945, AP-101, AS-202, Arimoclomol, ALZT-OP1a, AT1501, HK001, Q-Cells, Verdiperstat, NPT 520-34, RT001, SLS-005, among others. Reach out @ Amyotrophic Lateral Sclerosis Pipeline: Novel therapies and Emerging technologies Table of Contents Visit to know more of what’s covered @ ALS Emerging Therapies, Treatments and Ongoing Clinical Trials Related Reports Amyotrophic Lateral Sclerosis Als MarketDelveInsight's "Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology, and Market Forecast-2030" report. Acute Coronary Syndrome MarketDelveInsight's "Acute Coronary Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report. Acute Ischemic Stroke Ais MarketDelveInsight's "Acute ischemic stroke (AIS) - Market Insights, Epidemiology, and Market Forecast-2030" report. Cervical Dystonia MarketDelveInsight's "Cervical Dystonia - Market Insights, Epidemiology, and Market Forecast-2030" report. Chronic Neuropathic Pain MarketDelveInsight's "Chronic Neuropathic Pain - Market Insights, Epidemiology, and Market Forecast-2030" report. Charcot Marie Tooth Disease MarketDelveInsight's "Charcot-Marie-Tooth Disease - Market Insights, Epidemiology, and Market Forecast-2030" report. Related Posts 10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment LandscapeBurden And The Impact Of Mental Health Schizophrenia Market and Key Companies About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

100 Deals associated with Sotuletinib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 2	United States	Novartis Pharmaceuticals Corp.	30 Dec 2019
Amyotrophic Lateral Sclerosis	Phase 2	Finland	Novartis Pharmaceuticals Corp.	30 Dec 2019
Amyotrophic Lateral Sclerosis	Phase 2	Sweden	Novartis Pharmaceuticals Corp.	30 Dec 2019
Advanced Malignant Solid Neoplasm	Phase 2	United States	Novartis Pharmaceuticals Corp.	21 Oct 2016
Advanced Malignant Solid Neoplasm	Phase 2	Japan	Novartis Pharmaceuticals Corp.	21 Oct 2016
Advanced Malignant Solid Neoplasm	Phase 2	Israel	Novartis Pharmaceuticals Corp.	21 Oct 2016
Advanced Malignant Solid Neoplasm	Phase 2	Italy	Novartis Pharmaceuticals Corp.	21 Oct 2016
Advanced Malignant Solid Neoplasm	Phase 2	Singapore	Novartis Pharmaceuticals Corp.	21 Oct 2016
Advanced Malignant Solid Neoplasm	Phase 2	Spain	Novartis Pharmaceuticals Corp.	21 Oct 2016
Advanced Malignant Solid Neoplasm	Phase 2	Switzerland	Novartis Pharmaceuticals Corp.	21 Oct 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02829723 (AACR2024) Manual	Phase 1/2	Solid tumor \| Glioblastoma	-	BLZ945	qrtakhpeec(xmwgeimfao) = Downregulated genes have been noted as macrophage-specific genes, suggesting that treatment with BLZ945 is downregulating macrophages in the tumor microenvironment. lcsnklispr (xdxorypiec )	Positive	05 Apr 2024
				BLZ945 + spartalizumab
NCT02829723 (CT171, AACR2020) Manual	Phase 1/2	Advanced Malignant Solid Neoplasm	146	BLZ945 Q1W	tjmqrjljjd(nzqkhsxyvk) = acssdkqeya jszsubepdg (uecfutpfuz ) View more	Positive	15 Aug 2020
				BLZ945 + spartalizumab	tjmqrjljjd(nzqkhsxyvk) = tzwtskwvaz jszsubepdg (uecfutpfuz ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis